Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lars Lindholm(Umeå University), Steven Snapinn(United States Military Academy), Hans Wedel(Sahlgrenska University Hospital), Krister Kristiansson(MSD (Sweden)), Peter Aurup(United States Military Academy), Björn Dahlöf(Thermo Fisher Scientific (Sweden)), Per Omvik(Haukeland University Hospital), Ulf dé Fairé(Karolinska Institutet), Markku S. Nieminen(Cornell University), Ole Lederballe‐Pedersen(Regionshospitalet Viborg), Sverre E. Kjeldsen(Oslo University Hospital), Hans Ibsen(Glostrup Hospital), Frej Fyhrquist(Helsinki University Hospital), Jonathan M. Edelman(United States Military Academy), Richard B. Devereux(NewYork–Presbyterian Hospital), Suzanne Oparil(University of Alabama at Birmingham), Stevo Julius, Gareth Beevers(Birmingham City Hospital)
Cited by 1,571
Related Papers
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
|The Lancet|1998|5.8k
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
|New England Journal of Medicine|2004|4.5k